Sjuts Dustin S 4
4 · Revance Therapeutics, Inc. · Filed Dec 18, 2023
Insider Transaction Report
Form 4
Sjuts Dustin S
Chief Commercial Officer
Transactions
- Tax Payment
Common Stock
2023-12-15$8.08/sh−4,712$38,073→ 157,354 total
Footnotes (1)
- [F1]Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award (the "RSA") for 11,973 shares. The RSA vests in three equal annual installments from December 15, 2021.